Background: Although androgen-deprivation therapy (ADT) is the foundation of treatment for prostate cancer, the physiological impacts of ADT result in functional decline and enhanced risk of chronic disease and metabolic syndrome. Purpose: The Individualized Diet and Exercise Adherence Pilot Trial (IDEA-P) is a single-blind, randomized, pilot trial comparing the effects of a group-mediated, cognitive-behavioral (GMCB) exercise and dietary intervention (EX+D) with those of a standard-of-care (SC) control during the treatment of prostate cancer patients undergoing ADT. Methods: A total of 32 prostate cancer patients (M age = 66.28, SD = 7.79) undergoing ADT were randomly assigned to the 12-week EX+D intervention (n = 16) or control (n = 16). The primary outcome in IDEA-P was change in mobility performance with secondary outcomes including body composition and muscular strength. Blinded assessment of outcomes were obtained at baseline and at 2- and 3-month follow-ups. Results: Favorable adherence and retention rates were observed, and no serious intervention-related adverse events were documented. Intent-to-treat ANCOVA controlling for baseline value and ADT duration demonstrated that EX+D resulted in significantly greater improvements in mobility performance (p < .02), muscular strength (p < .01), body fat percentage (p < .05), and fat mass (p < .03) at 3-month follow-up, relative to control. Conclusion: Findings from the IDEA-P trial suggest that a GMCB-based EX+D intervention resulted in significant, clinically meaningful improvements in mobility performance, muscular strength, and body composition, relative to controls. Collectively, these results suggest that the EX+D was a safe and well-tolerated intervention for prostate cancer patients on ADT. The utility of implementing this approach in the treatment of prostate cancer patients on ADT should be evaluated in future large-scale efficacy trials. Clinical Trial information: NCT02050906.
RCT Entities:
Background: Although androgen-deprivation therapy (ADT) is the foundation of treatment for prostate cancer, the physiological impacts of ADT result in functional decline and enhanced risk of chronic disease and metabolic syndrome. Purpose: The Individualized Diet and Exercise Adherence Pilot Trial (IDEA-P) is a single-blind, randomized, pilot trial comparing the effects of a group-mediated, cognitive-behavioral (GMCB) exercise and dietary intervention (EX+D) with those of a standard-of-care (SC) control during the treatment of prostate cancerpatients undergoing ADT. Methods: A total of 32 prostate cancerpatients (M age = 66.28, SD = 7.79) undergoing ADT were randomly assigned to the 12-week EX+D intervention (n = 16) or control (n = 16). The primary outcome in IDEA-P was change in mobility performance with secondary outcomes including body composition and muscular strength. Blinded assessment of outcomes were obtained at baseline and at 2- and 3-month follow-ups. Results: Favorable adherence and retention rates were observed, and no serious intervention-related adverse events were documented. Intent-to-treat ANCOVA controlling for baseline value and ADT duration demonstrated that EX+D resulted in significantly greater improvements in mobility performance (p < .02), muscular strength (p < .01), body fat percentage (p < .05), and fat mass (p < .03) at 3-month follow-up, relative to control. Conclusion: Findings from the IDEA-P trial suggest that a GMCB-based EX+D intervention resulted in significant, clinically meaningful improvements in mobility performance, muscular strength, and body composition, relative to controls. Collectively, these results suggest that the EX+D was a safe and well-tolerated intervention for prostate cancerpatients on ADT. The utility of implementing this approach in the treatment of prostate cancerpatients on ADT should be evaluated in future large-scale efficacy trials. Clinical Trial information: NCT02050906.
Authors: Joe L Rowles; Joshua W Smith; Catherine C Applegate; Rita J Miller; Matthew A Wallig; Amandeep Kaur; Jesus N Sarol; Salma Musaad; Steven K Clinton; William D O'Brien; John W Erdman Journal: J Nutr Date: 2020-07-01 Impact factor: 4.798
Authors: Robert U Newton; Claus T Christophersen; Ciaran M Fairman; Nicolas H Hart; Dennis R Taaffe; David Broadhurst; Amanda Devine; Raphael Chee; Colin I Tang; Nigel Spry; Daniel A Galvão Journal: BMJ Open Date: 2019-04-14 Impact factor: 2.692
Authors: Amit Algotar; Chiu-Hsieh Hsu; H H Sherry Chow; Shona Dougherty; Hani M Babiker; David Marrero; Ivo Abraham; Rachit Kumar; Jennifer Ligibel; Kerry S Courneya; Cynthia Thomson Journal: JMIR Res Protoc Date: 2019-02-05
Authors: Alexander R Lucas; Rhonda L Bitting; Jason Fanning; Scott Isom; W Jack Rejeski; Heidi D Klepin; Stephen B Kritchevsky Journal: PLoS One Date: 2020-02-13 Impact factor: 3.240
Authors: Colleen K Spees; Ashlea C Braun; Emily B Hill; Elizabeth M Grainger; James Portner; Gregory S Young; Matthew D Kleinhenz; Chureeporn Chitchumroonchokchai; Steven K Clinton Journal: J Oncol Date: 2019-11-21 Impact factor: 4.375
Authors: Ciaran M Fairman; Krissy L Kendall; Robert U Newton; Nicolas H Hart; Dennis R Taaffe; Raphael Chee; Colin I Tang; Daniel A Galvão Journal: BMJ Open Date: 2019-09-20 Impact factor: 2.692
Authors: Brian C Focht; Alexander R Lucas; Elizabeth Grainger; Christina Simpson; Ciaran M Fairman; Jennifer M Thomas-Ahner; Zachary L Chaplow; Victoria R DeScenza; Jessica Bowman; Steven K Clinton Journal: Integr Cancer Ther Date: 2019 Jan-Dec Impact factor: 3.077
Authors: Rebekah L Wilson; Dennis R Taaffe; Robert U Newton; Nicolas H Hart; Philippa Lyons-Wall; Daniel A Galvão Journal: Nutrients Date: 2021-05-14 Impact factor: 5.717
Authors: Rebekah L Wilson; Robert U Newton; Dennis R Taaffe; Nicolas H Hart; Philippa Lyons-Wall; Daniel A Galvão Journal: Med Sci Sports Exerc Date: 2021-03-01